(part of Biotech Week)
Stop by our booth #1119
DON’T MISS OUTSOURCED PHARMA CAPACITY
Resilience is excited to participate and provide an overview of biologics & vaccines drug substance manufacturing and drug product & fill/finish capabilities at our key North American sites.
You will hear from Stewart McNaull, Business Head, Biologics & Vaccines Franchise, and Nithin Stephen, Director of Commercial Development, Drug Product, on how Resilience can support your development & GMP manufacturing needs.
October 11, 2022
Home to our Development and Manufacturing Center for Biologics, Vaccines, and Gene Therapy, our Alachua site is answering the call to revolutionize how medicines are made, funded, and scaled.
Sign up to hear from site leaders and virtually tour our recently built process and analytical development laboratory and GMP manufacturing facility which includes four additional 2,000L single-use bioreactors.
Speakers:
Stewart McNaull, VP and Business Head of Vaccines and Biologics
Oliver Vogt, VP and GM Site Head – Alachua site
Suzanne Mace, Head of Process Development – Alachua site
Chuck Hart, Head of Manufacturing – Alachua site
Adam Pinkert, Head of Quality – Alachua site
OCTOBER 9-12, 2022
CARLSBAD, CA
Scalable biomanufacturing for cell and gene therapies is crucial to making them accessible to more patients. However, gaps in capacity and technologies are holding these life-saving therapies back from becoming mainstream options. The industry needs bold ideas and better ways to make them quickly, reliably, and at scale.
Join Resilience’s cell therapy leaders Eytan Abraham – VP and Business Head of Cell Therapy, Gene Therapy, and Nucleic Acid Franchises and Bruce Thompson – VP and Technical Head of Cell Therapy Franchise and a panel of industry experts as they lead a thought-provoking discussion on key industry challenges and how we can solve these bottlenecks to future-proof life-saving therapies.
Speakers: Marta Papini, Tom Ransohoff, Stewart McNaull
The need for advanced technology platforms that offer a clear, end-to-end path to commercial manufacturing is driving biotech companies to outsource critical stages of their biomanufacturing process.
In this informative webinar, biotech leaders provide thought-provoking examples of applying a stage-gate approach throughout the drug development lifecycle. The information presented will highlight how to perform critical activities leveraging process and analytical development resources from early-stage clinical to commercialization.
JULY 26th, 2:45 pm ET
Amanda Ashcraft
Senior Director, Quality Site Head
“The Role of Commercial Manufacturing in Innovation”
JULY 26th, 2:45 pm ET
Bruce Thompson, PhD
Vice President & Technical Lead, Cell Therapy
“When Art Meets Science: Tech Transfer in the Age of New Modalities”
JULY 27th, 1:15 pm ET
David DiGiusto
Sr. Vice President, Stem Cells and Regenerative Medicine
“Cell-Based Therapies: This Time It Really *Is* Different!”
Hilton Boston Logan Airport | Boston, MA
Visit our team Booth #23
Rutgers University Busch Campus Center
Piscataway, New Jersey
July 7TH, 1:20 pm ET
Join Resilience Co-Founder and CEO, to hear how the gap between bio-manufacturing supply and demand is being solved for.
San Diego, CA
Visit with us at Booth 1011
JUNE 14TH, 12:00 pm – 12:45 pm
Eytan Abraham, PhD
Vice President & Business Head of Cell Therapy
Panel: Therapeutic Cell and Gene therapy Modalities – Business and Manufacturing Strategies Impacting the Decision to Develop One Therapy Type vs. Another
See more Info here
JUNE 14TH, 12:45 pm – 1:05 pm
Weston Kightlinger, PhD
Director, Cell-free Protein Synthesis
Presentation: Enabling Next-Generation Biomanufacturing Using Cell-free Technology
More info coming soon
JUNE 15TH, 11:00 am – 12:00 pm
John Kerwin, PhD
Technical Head of Gene Therapy
Panel: Current Realities of Make vs. Buy for Advanced Therapies in Manufacturing
See more Info here
JUNE 15TH, 12:00 pm – 12:45 pm
Bruce Thompson, PhD
Vice President & Technical Lead, Cell Therapy
Panel: Therapeutic Cell and Gene Therapy Introducing New Technologies to Compress Timelines, Increase Capacity and Reduce Risk
See more Info here
San Francisco, CA
Visit with us at Booth 107
Join us for a presentation on March 9th at 12:30pm, “High-Throughput platforms for Gene Therapy Programs”, Presented by Patrick Starremans, PhD is Director of Analytical Development and Head of Resilience’s Gene-therapy AD-group.
Key topics to be presented on:
Anytime during the week, stop by our booth (#19) to learn how we can help you by revolutionizing the way medicines are made.
Resilience, Director of Analytical Development and Head of Resilience’s Gene-therapy AD-group
Patrick Starremans, PhD is Director of Analytical Development and head of Resilience’s Gene-therapy AD-group. Dr. Starremans received his PhD in Medical Sciences and Master’s in Medical Biology from the Radboud University in Nijmegen the Netherlands and an undergraduate degree in Biochemistry from Zuyd University of Applied Sciences. Following his move to the US, his career focused on molecular and cell-based assay development for the past 18 years, starting at Harvard Medical School and followed by tenures in pharmacology at Genzyme, Sanofi, Evotec and Mitobridge followed by a switch to Gene Therapy Analytical Development when he joined Voyager Therapeutics as head of Process Analytics and later as head of Analytical Development building out their CMC-Analytical capabilities and infrastructure and helping Voyager file their first successful IND for an internal program.
Join us for a panel discussion on January 27th at 12:30pm, “Technology, Disruptive Innovation and Partnerships that are revolutionizing How Medicines Are Made“, moderated by our very own David DiGiusto, CTO of Cell and Gene Therapy. Panelists will include an array of industry experts including Resilience team members: Bruce Thompson., VP & Technical Lead, Cell Therapy and John Kerwin, Senior Director & Technical Head, Gene Therapy.
The technology of manufacturing complex medicines like cell and gene therapy hasn’t kept pace with the wave of scientific discoveries fueling them. Because many of these approaches to attacking diseases are so new, the process of making them hasn’t progressed beyond methods only meant for small batch, academic labs. In this panel discussion, we will take a deeper look into what has hindered growth and scalability of these medicines, and how disruptive technology and cross-industry partnerships are driving change in this young and exciting field of medicine.
Key topics:
Anytime during the week, stop by our booth (#201) to learn how we can help you by revolutionizing the way medicines are made.
Resilience, Chief Technology Officer, Cell & Gene Therapy
David DiGiusto PhD is formally trained as an immunologist and stem cell biologist with over 20 years of academic and 12 years of industrial experience in translational medicine with a focus on Cell and Genetic therapies. Dr. DiGiusto has made significant contributions to product development and manufacturing for more than a dozen Phase I/II clinical trials. He has led the creation and/or operation of 11 GMP compliant biologics manufacturing facilities including the oversight of process development, manufacturing, quality systems, and regulatory affairs infrastructure. Under his direction, plasmid DNA, CAR T-cells, regulatory T-cells, engineered stem cell grafts, gene modified hematopoietic stem cell and ES derived cell therapy products have been developed, manufactured and used in first in human and early stage clinical investigations. Dr. DiGiusto is the former North American Vice President for ISCT (2016-2018), former member of the NIH recombinant DNA advisory committee (RAC) and an independent biotechnology consultant (>30 years). He received his undergraduate and Ph.D. degrees from the University of Colorado.
We’re constantly looking for builders, creatives, and innovators who want to make big change and serve an important mission.
